Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Wednesday, August, 9th. The company reported ($1.34) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by $0.12. The firm had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm's revenue was up 82.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.05) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Alnylam Pharmaceuticals.

20 analysts have issued 1-year target prices for Alnylam Pharmaceuticals' stock. Their predictions range from $50.00 to $146.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $94.60 in the next year. View Analyst Ratings for Alnylam Pharmaceuticals.

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

• 1. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)
• 2. Chardan Capital analysts commented, "We believe far and away the least likely scenario is that patisiran fails to demonstrate efficacy in APOLLO, considering that, as discussed above, the clinical effect of TTR silencing has been de- risked by top-line results from NEURO-TTR. A significant disconnect between the APOLLO and NEURO-TTR studies is, in our view, only possible if, as discussed in the 9 January 2017 company note, the differences in the patient population between the phase II OLE and APOLLO study (APOLLO has more advanced patients than the phase II OLE) leads to a slower rate of mNIS+7 increase in the placebo arm than is expected in natural history since, to our understanding, the NEURO-TTR patient population is likely somewhere between the phase II OLE and APOLLO populations." (8/10/2017)
• 3. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)

Some companies that are related to Alnylam Pharmaceuticals include Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Portola Pharmaceuticals (PTLA).

Alnylam Pharmaceuticals' management team includes the folowing people:

• Michael W. Bonney, Independent Chairman of the Board
• Barry E. Greene, President
• John M. Maraganore Ph.D., Chief Executive Officer, Director
• Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer
• Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President
• Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development
• Laurie B. Keating, Senior Vice President, General Counsel, Secretary
• Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
• Theresa Heggie, Senior Vice President, Head of Europe and Canada
• Peter F. Smith Ph.D., Senior Vice President - Early Development

Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.92%), Dodge & Cox (10.66%), Vanguard Group Inc. (7.45%), BlackRock Inc. (6.02%), Baillie Gifford & Co. (3.98%) and State Street Corp (2.11%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., State Street Corp, Dodge & Cox, Balyasny Asset Management LLC, Rockefeller Financial Services Inc., Wells Fargo & Company MN, Tekla Capital Management LLC and Pictet Asset Management Ltd.. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Janus Henderson Group PLC, BlackRock Inc., TIAA CREF Investment Management LLC, PDT Partners LLC, Farallon Capital Management LLC and Broadfin Capital LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $113.78.